You are here

  • Home
  • Archive
  • Volume 15, Issue 3
  • NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study

Citation Tools

Article menu

Download PDFPDF

Oncology
Protocol
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Roesch RM, Schnorbach J, Klotz LV, et al
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study
BMJ Open 2025;15:e096617. doi: 10.1136/bmjopen-2024-096617